Preview agenda announcement - Americas Antibody Congress

Announcing the release of the preview agenda – Americas Antibody Congress

The preview agenda for Americas Antibody Congress 2016 is now LIVE. Download the preview agenda here > Join us in San Diego next May for an expanded two-day event and deeper content than ever before in: Antibody Engineering Oncology Infectious Diseases ADCs/Bioconjugates Download the preview agenda here to find out more about the content on offer > That’s four full …

Download: Engineering scFv-based bifunctionals for sub-cutaneous delivery

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr William Finlay, Director, Protein Discovery …

Download: Novel protease-resistant mAb platform engineered for use in anti-cancer and anti-microbial therapeutics

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Randall Brezski, Senior Scientist, Biotechnology Center of Excellence, …

Download Presentation: Engineering strategies to generate site-specific ADC’s

Developing therapeutic monoclonal antibodies and ADC's is a key focus of the pharmaceutical industry's R&D. The European Antibody Congress 2012 bought together senior level executives and opinion leaders from around the globe to further their knowledge and engage in discussion on a variety of topics relating to mAbs, ADC's and bispecifics. Attendees at this highly successful event were fortunate enough …